Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces that data from two Phase 3 clinical studies of PRISTIQ(TM) (desvenlafaxine), an investigational serotonin-norepinephrine reuptake inhibitor (SNRI), showed that adult patients who received a 50 mg/day dose of PRISTIQ for the treatment of major depressive disorder (MDD) experienced a statistically significant reduction in the symptoms of major depression compared to placebo. [click link for full article]
Popularity: 1% [?]
Related posts:
- New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms Of Major Depressive Disorder Versus Placebo
- Wyeth’s Pristiq, A New Treatment For Major Depressive Disorder
- Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement In Symptoms Of Depression In Adult Patients Versus Placebo
- FDA Approves Pristiq For The Treatment Of Adult Patients With Major Depressive Disorder
- New Study Results Provide Additional Data About Short- And Long-Term Use Of Desvenlafaxine Succinate In The Treatment Of Major Depressive Disorder
Comments
No Responses to “New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms Of Major Depressive Disorder Versus Placebo”